Study Examines Disparities in CLL Among Different Races and Socioeconomic Backgrounds

Dr. Ira Zackon, a hematologist/oncologist with New York Oncology Hematology and a senior medical director with Ontada, a data science company part of McKesson, recently discussed a real-world study that aimed to identify racial and socioeconomic disparities in patients with chronic lymphocytic leukemia (CLL). The study specifically focused on comparing outcomes for Black and White patient populations with CLL in community oncology settings. Researchers analyzed data from over 12,000 patients with CLL between 2015 and 2023, coinciding with the introduction of new, effective therapies for CLL.

In CLL, treatment approaches have evolved with the introduction of BTK inhibitors, BCL2 inhibitors, and antibodies that have significantly improved patient outcomes. Despite these advancements, researchers recognize the impact of social determinants of health on patient outcomes beyond just the effectiveness of treatments. Factors such as race and socioeconomic status can play a role in influencing CLL treatment and outcomes.

The study utilized the iKnowMed electronic health record system, which is part of the US Oncology Network, representing a large group of community oncologists across the country. By analyzing data from a diverse patient population, spanning approximately eight years from 2015 to 2023, researchers were able to gain insights into how race and socioeconomic factors may influence CLL treatment and outcomes in real-world settings. This research sheds light on the importance of addressing disparities in healthcare to ensure equitable access to the best possible care for all CLL patients.